002020 京新药业
交易中 08-24 13:31:30
资讯
新帖
简况
京新药业:公司盐酸卡立哌嗪已经获批
证券之星 · 08:45
京新药业:公司盐酸卡立哌嗪已经获批
新股消息 | 京新药业(002020.SZ)港股IPO招股书失效
智通财经 · 08-11
新股消息 | 京新药业(002020.SZ)港股IPO招股书失效
股市必读:京新药业(002020)8月7日董秘有最新回复
证券之星 · 08-10
股市必读:京新药业(002020)8月7日董秘有最新回复
京新药业:公司回购已经在进行中
证券之星 · 08-06
京新药业:公司回购已经在进行中
京新药业:公司坚定创新转型
证券之星 · 08-05
京新药业:公司坚定创新转型
京新药业:公司盐酸卡立哌嗪已经获批
证券之星 · 08-05
京新药业:公司盐酸卡立哌嗪已经获批
股市必读:京新药业新发布《关于股份回购进展公告》
证券之星 · 08-05
股市必读:京新药业新发布《关于股份回购进展公告》
股市必读:京新药业新发布《关于股份回购进展公告》
证券之星 · 08-04
股市必读:京新药业新发布《关于股份回购进展公告》
京新药业:公司盐酸卡立哌嗪已经获批
证券之星 · 07-24
京新药业:公司盐酸卡立哌嗪已经获批
京新药业(002020)披露首次回购公司股份公告,7月23日股价上涨0.07%
证券之星 · 07-23
京新药业(002020)披露首次回购公司股份公告,7月23日股价上涨0.07%
京新药业公布国际专利申请:“苯并二氮杂*衍生物用于治疗合并不同疾病的失眠”
证券之星 · 07-22
京新药业公布国际专利申请:“苯并二氮杂*衍生物用于治疗合并不同疾病的失眠”
京新药业公布国际专利申请:“苯并二氮杂*类化合物用于治疗失眠”
证券之星 · 07-21
京新药业公布国际专利申请:“苯并二氮杂*类化合物用于治疗失眠”
京新药业(002020)披露回购公司股份用于注销并减少注册资本的议案,7月20日股价上涨4.41%
证券之星 · 07-20
京新药业(002020)披露回购公司股份用于注销并减少注册资本的议案,7月20日股价上涨4.41%
京新药业:公司的盐酸考来维仑片在正常审评中
证券之星 · 07-20
京新药业:公司的盐酸考来维仑片在正常审评中
7月17日京新药业跌7.06%,兴业医疗保健混合A基金重仓该股
证券之星 · 07-17
7月17日京新药业跌7.06%,兴业医疗保健混合A基金重仓该股
京新药业(002020)披露回购股份事项前十名股东持股情况公告,7月16日股价下跌2.87%
证券之星 · 07-16
京新药业(002020)披露回购股份事项前十名股东持股情况公告,7月16日股价下跌2.87%
京新药业:盐酸卡立哌嗪胶囊已获得药品注册证书
证券之星 · 07-15
京新药业:盐酸卡立哌嗪胶囊已获得药品注册证书
7月14日京新药业涨5.06%,兴业医疗保健混合A基金重仓该股
证券之星 · 07-14
7月14日京新药业涨5.06%,兴业医疗保健混合A基金重仓该股
股市必读:京新药业(002020)7月10日董秘有最新回复
证券之星 · 07-13
股市必读:京新药业(002020)7月10日董秘有最新回复
研报掘金丨东方证券:维持京新药业“买入”评级,重磅首仿获批,回购彰显信心
格隆汇 · 07-10
研报掘金丨东方证券:维持京新药业“买入”评级,重磅首仿获批,回购彰显信心
加载更多
公司概况
公司名称:
浙江京新药业股份有限公司
所属行业:
医药制造业
上市日期:
2004-07-15
主营业务:
浙江京新药业股份有限公司的主营业务是化学制剂、传统中药、生物制剂、化学原料药、医疗器械的研发、生产及销售。公司的主要产品是化学制剂、中成药、生物制剂、化学原料药、医疗器械。公司是第一批“中国医药企业制剂国际化先导企业”,连续多年荣登“中国化学制药行业制剂出口型优秀企业品牌”、“中国医药工业百强”和“中国化学制药企业百强榜”。
发行价格:
10.05
{"stockData":{"symbol":"002020","market":"SZ","secType":"STK","nameCN":"京新药业","latestPrice":12.73,"timestamp":1787549490000,"preClose":13.18,"halted":0,"volume":10404100,"delay":0,"changeRate":-0.0341,"floatShares":724000000,"shares":861000000,"eps":0.8826,"marketStatus":"交易中","change":-0.45,"latestTime":"08-24 13:31:30","open":13.15,"high":13.21,"low":12.69,"amount":134000000,"amplitude":0.0395,"askPrice":12.74,"askSize":141,"bidPrice":12.73,"bidSize":85,"shortable":0,"etf":0,"ttmEps":0.8826,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1787554800000},"marketStatusCode":2,"adr":0,"adjPreClose":13.18,"symbolType":"stock","openAndCloseTimeList":[[1787535000000,1787542200000],[1787547600000,1787554800000]],"highLimit":14.5,"lowLimit":11.86,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":861029140,"isCdr":false,"pbRate":1.86,"roa":"--","peRate":14.423295,"roe":"2.76%","epsLYR":0.92,"committee":0.455352,"marketValue":10961000000,"turnoverRate":0.0144,"status":1,"floatMarketCap":9216000000},"requestUrl":"/m/hq/s/002020","defaultTab":"news","newsList":[{"id":"2661241782","title":"京新药业:公司盐酸卡立哌嗪已经获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2661241782","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661241782?lang=zh_cn&edition=full","pubTime":"2026-08-24 08:45","pubTimestamp":1787532311,"startTime":"0","endTime":"0","summary":"证券之星消息,京新药业(002020)08月24日在投资者关系平台上答复投资者关心的问题。投资者提问:问吕董,公司准创新药盐酸卡立哌嗪开始上市销售了吗?如果没有预计什么时间开始销售。零外公司地达西尼销量是否继续同步增长?京新药业回复:您好!公司盐酸卡立哌嗪已经获批,公司会尽快做好生产计划,安排上市销售。地达西尼的销售也在积极推进中。谢谢!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:陈思雨","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082400002690.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658917957","title":"新股消息 | 京新药业(002020.SZ)港股IPO招股书失效","url":"https://stock-news.laohu8.com/highlight/detail?id=2658917957","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658917957?lang=zh_cn&edition=full","pubTime":"2026-08-11 06:16","pubTimestamp":1786400190,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,浙江京新药业股份有限公司(简称:京新药业,002020.SZ)于2026年2月11日所递交的港股招股书满6个月,于2026年8月11日失效,递表时中信证券为其独家保荐人。据此前招股书披露,京新药业是一家以创新为驱动力的制药集团,策略重点专注于两大核心疾病领域:中枢神经系统疾病;及心血管及脑血管疾病。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478255.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4127","FRHC","BK4585","BK4588","KCAI","REDS","VXUS","IPOS","002020","BK0239","KCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658670438","title":"股市必读:京新药业(002020)8月7日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2658670438","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658670438?lang=zh_cn&edition=full","pubTime":"2026-08-10 01:26","pubTimestamp":1786296372,"startTime":"0","endTime":"0","summary":"截至2026年8月7日收盘,京新药业报收于14.38元,上涨5.35%,换手率4.6%,成交量33.28万手,成交额4.67亿元。董秘最新回复投资者: 问吕董,公司和没德信息在Al全景应用方面合作,主要体现在什么方面?公司港股上市在正常推进中,JX2201降脂新药临床II期正常推进中。交易信息汇总资金流向8月7日主力资金净流出1193.94万元,占总成交额2.56%;游资资金净流出1355.18万元,占总成交额2.9%;散户资金净流入2549.12万元,占总成交额5.46%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081000000622.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657663101","title":"京新药业:公司回购已经在进行中","url":"https://stock-news.laohu8.com/highlight/detail?id=2657663101","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657663101?lang=zh_cn&edition=full","pubTime":"2026-08-06 20:51","pubTimestamp":1786020685,"startTime":"0","endTime":"0","summary":"证券之星消息,京新药业(002020)08月05日在投资者关系平台上答复投资者关心的问题。投资者提问:问吕董,口口声声说尽快回购,现在所有程序已完成,公司回购了吗?不要停在口头上?京新药业回复:您好!公司回购已经在进行中,具体回购进展请看相关公告。谢谢!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080600037553.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657511523","title":"京新药业:公司坚定创新转型","url":"https://stock-news.laohu8.com/highlight/detail?id=2657511523","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657511523?lang=zh_cn&edition=full","pubTime":"2026-08-05 16:06","pubTimestamp":1785917171,"startTime":"0","endTime":"0","summary":"证券之星消息,京新药业(002020)08月05日在投资者关系平台上答复投资者关心的问题。投资者提问:问吕董,为了公司向创新药转型公司都发行H股,然而公司在转型创新药方面做了什么?有什么储备?京新药业回复:您好!公司坚定创新转型,目前创新项目在正常推进中,具体情况敬请关注定期报告,谢谢!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500027781.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657115405","title":"京新药业:公司盐酸卡立哌嗪已经获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2657115405","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657115405?lang=zh_cn&edition=full","pubTime":"2026-08-05 16:06","pubTimestamp":1785917170,"startTime":"0","endTime":"0","summary":"证券之星消息,京新药业(002020)08月05日在投资者关系平台上答复投资者关心的问题。投资者提问:公司准新药盐酸卡立哌嗪获批已一个月了,对外销售开始了吗?京新药业回复:您好!公司盐酸卡立哌嗪已经获批,公司会尽快做好生产计划,安排上市销售。谢谢!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500027780.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657565911","title":"股市必读:京新药业新发布《关于股份回购进展公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2657565911","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657565911?lang=zh_cn&edition=full","pubTime":"2026-08-05 02:49","pubTimestamp":1785869350,"startTime":"0","endTime":"0","summary":"截至2026年8月4日收盘,京新药业报收于13.74元,上涨0.51%,换手率1.98%,成交量14.31万手,成交额1.97亿元。公司公告汇总:截至2026年7月31日,京新药业已回购股份100.63万股,成交总金额1385.2001万元,回购进展符合相关法规及既定方案。公司公告汇总关于股份回购进展公告浙江京新药业股份有限公司于2026年7月2日召开第九届董事会第五次会议,7月20日召开2026年第二次临时股东会,审议通过《关于回购公司股份用于注销并减少注册资本的议案》。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500002346.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656305021","title":"股市必读:京新药业新发布《关于股份回购进展公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2656305021","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656305021?lang=zh_cn&edition=full","pubTime":"2026-08-04 02:08","pubTimestamp":1785780498,"startTime":"0","endTime":"0","summary":"截至2026年8月3日收盘,京新药业报收于13.67元,上涨0.22%,换手率1.37%,成交量9.89万手,成交额1.36亿元。公司公告汇总:截至2026年7月31日,京新药业已回购股份100.63万股,成交总金额1385.2001万元,回购进展符合既定方案。公司公告汇总关于股份回购进展公告浙江京新药业股份有限公司于2026年7月2日召开第九届董事会第五次会议,7月20日召开2026年第二次临时股东会,审议通过《关于回购公司股份用于注销并减少注册资本的议案》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080400001579.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653702171","title":"京新药业:公司盐酸卡立哌嗪已经获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2653702171","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653702171?lang=zh_cn&edition=full","pubTime":"2026-07-24 15:54","pubTimestamp":1784879655,"startTime":"0","endTime":"0","summary":"证券之星消息,京新药业(002020)07月24日在投资者关系平台上答复投资者关心的问题。投资者提问:问吕董,公司准新药盐酸卡立哌嗪开始市场销售了吗?京新药业回复:您好!公司盐酸卡立哌嗪已经获批,公司会尽快做好生产计划,安排上市销售。谢谢!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:沈彬","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072400024408.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653295617","title":"京新药业(002020)披露首次回购公司股份公告,7月23日股价上涨0.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2653295617","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653295617?lang=zh_cn&edition=full","pubTime":"2026-07-23 22:38","pubTimestamp":1784817493,"startTime":"0","endTime":"0","summary":"截至2026年7月23日收盘,京新药业报收于14.15元,较前一交易日上涨0.07%,最新总市值为121.84亿元。该股当日开盘13.98元,最高14.22元,最低13.78元,成交额达2.33亿元,换手率为2.29%。近日,京新药业披露《关于首次回购公司股份的公告》。本次回购符合相关法律法规及公司既定回购方案。公司后续将根据市场情况继续实施回购,并按规定履行信息披露义务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072300048260.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653787382","title":"京新药业公布国际专利申请:“苯并二氮杂*衍生物用于治疗合并不同疾病的失眠”","url":"https://stock-news.laohu8.com/highlight/detail?id=2653787382","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653787382?lang=zh_cn&edition=full","pubTime":"2026-07-22 09:55","pubTimestamp":1784685322,"startTime":"0","endTime":"0","summary":"证券之星消息,根据企查查数据显示京新药业(002020)公布了一项国际专利申请,专利名为“苯并二氮杂*衍生物用于治疗合并不同疾病的失眠”,专利申请号为PCT/CN2025/071433,国际公布日为2026年7月16日。专利详情如下:图片来源:世界知识产权组织(WIPO)今年以来京新药业已公布的国际专利申请3个,较去年同期增加了200%。结合公司2025年年报财务数据,2025年公司在研发方面投入了3.68亿元,同比减4.04%。数据来源:企查查以上内容为证券之星据公开信息整理,不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072200017374.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653824991","title":"京新药业公布国际专利申请:“苯并二氮杂*类化合物用于治疗失眠”","url":"https://stock-news.laohu8.com/highlight/detail?id=2653824991","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653824991?lang=zh_cn&edition=full","pubTime":"2026-07-21 05:54","pubTimestamp":1784584456,"startTime":"0","endTime":"0","summary":"证券之星消息,根据企查查数据显示京新药业(002020)公布了一项国际专利申请,专利名为“苯并二氮杂*类化合物用于治疗失眠”,专利申请号为PCT/CN2025/071429,国际公布日为2026年7月16日。专利详情如下:图片来源:世界知识产权组织(WIPO)今年以来京新药业已公布的国际专利申请2个,较去年同期增加了100%。结合公司2025年年报财务数据,2025年公司在研发方面投入了3.68亿元,同比减4.04%。数据来源:企查查以上内容为证券之星据公开信息整理,不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072100004324.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652211141","title":"京新药业(002020)披露回购公司股份用于注销并减少注册资本的议案,7月20日股价上涨4.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2652211141","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652211141?lang=zh_cn&edition=full","pubTime":"2026-07-20 22:24","pubTimestamp":1784557460,"startTime":"0","endTime":"0","summary":"截至2026年7月20日收盘,京新药业报收于14.43元,较前一交易日上涨4.41%,最新总市值为124.25亿元。近日,京新药业发布《回购报告书》,披露公司拟使用自有资金以集中竞价交易方式回购公司股份,用于注销并减少注册资本。预计回购股份数量约为526.32万股至1,052.63万股,约占公司总股本的0.61%-1.22%。回购实施期限为自股东会审议通过之日起不超过12个月。公司已开立回购专用证券账户,并承诺全体董事本次回购不会损害公司债务履行能力和持续经营能力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072000039671.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652510299","title":"京新药业:公司的盐酸考来维仑片在正常审评中","url":"https://stock-news.laohu8.com/highlight/detail?id=2652510299","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652510299?lang=zh_cn&edition=full","pubTime":"2026-07-20 16:57","pubTimestamp":1784537844,"startTime":"0","endTime":"0","summary":"证券之星消息,京新药业(002020)07月20日在投资者关系平台上答复投资者关心的问题。投资者提问:请问盐酸考来维仑片目前还处于药监总局的正常审评中吗?京新药业回复:您好!公司的盐酸考来维仑片在正常审评中。谢谢!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072000025398.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652592406","title":"7月17日京新药业跌7.06%,兴业医疗保健混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652592406","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652592406?lang=zh_cn&edition=full","pubTime":"2026-07-17 16:40","pubTimestamp":1784277631,"startTime":"0","endTime":"0","summary":"证券之星消息,7月17日京新药业跌7.06%,收盘报13.82元,换手率4.04%,成交量29.22万手,成交额4.14亿元。根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共7家,其中持有数量最多的公募基金为兴业基金的兴业医疗保健混合A。兴业医疗保健混合A的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700030323.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651440293","title":"京新药业(002020)披露回购股份事项前十名股东持股情况公告,7月16日股价下跌2.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2651440293","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651440293?lang=zh_cn&edition=full","pubTime":"2026-07-16 22:14","pubTimestamp":1784211260,"startTime":"0","endTime":"0","summary":"截至2026年7月16日收盘,京新药业报收于14.87元,较前一交易日下跌2.87%,最新总市值为128.04亿元。近日,京新药业发布《关于回购股份事项前十名股东和前十名无限售条件股东持股情况的公告》。前十名股东中,吕钢持股178,796,755股,占比20.77%,为第一大股东;京新控股集团有限公司持股134,966,393股,占比15.68%。前十名无限售条件股东中,京新控股集团有限公司持股比例为18.64%,居首位。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071600040104.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651480974","title":"京新药业:盐酸卡立哌嗪胶囊已获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2651480974","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651480974?lang=zh_cn&edition=full","pubTime":"2026-07-15 08:48","pubTimestamp":1784076492,"startTime":"0","endTime":"0","summary":"证券之星消息,京新药业(002020)07月15日在投资者关系平台上答复投资者关心的问题。投资者提问:问吕董,公司准新药盐酸卡立哌嗪上市销售了吗?如果没有大约什么时间上市?今年有新药获批后不足十天就入院上架的。你获批已十多天了!京新药业回复:您好!盐酸卡立哌嗪胶囊已获得药品注册证书,公司会尽快安排上市销售。谢谢!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:陈思雨","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071500009809.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651033173","title":"7月14日京新药业涨5.06%,兴业医疗保健混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2651033173","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651033173?lang=zh_cn&edition=full","pubTime":"2026-07-14 16:25","pubTimestamp":1784017527,"startTime":"0","endTime":"0","summary":"证券之星消息,7月14日京新药业涨5.06%,收盘报14.73元,换手率5.44%,成交量39.39万手,成交额5.69亿元。根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共7家,其中持有数量最多的公募基金为兴业基金的兴业医疗保健混合A。兴业医疗保健混合A的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071400030505.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651650981","title":"股市必读:京新药业(002020)7月10日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2651650981","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651650981?lang=zh_cn&edition=full","pubTime":"2026-07-13 01:44","pubTimestamp":1783878252,"startTime":"0","endTime":"0","summary":"截至2026年7月10日收盘,京新药业报收于14.32元,上涨4.45%,换手率4.7%,成交量34.04万手,成交额4.78亿元。公司的盐酸卡立哌嗪胶囊已获得药品注册证书,请关注公司已经披露的公告。高峄期对比盐酸卡立哌嗪公司11502预计全球销售额将达300亿。反此一药毛利将达100亿以上。交易信息汇总资金流向7月10日主力资金净流出686.36万元,占总成交额0.0%;游资资金净流出1475.67万元,占总成交额0.0%;散户资金净流入2162.03万元,占总成交额0.0%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071300000882.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650907986","title":"研报掘金丨东方证券:维持京新药业“买入”评级,重磅首仿获批,回购彰显信心","url":"https://stock-news.laohu8.com/highlight/detail?id=2650907986","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650907986?lang=zh_cn&edition=full","pubTime":"2026-07-10 14:52","pubTimestamp":1783666366,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0028","600958","BK0276","BK0183","BK0188","002020","BK0012","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1787549493573,"stockEarnings":[{"period":"1week","weight":-0.0619},{"period":"1month","weight":-0.0679},{"period":"3month","weight":-0.0204},{"period":"6month","weight":-0.1849},{"period":"1year","weight":-0.3064},{"period":"ytd","weight":-0.2867}],"compareEarnings":[{"period":"1week","weight":-0.0056},{"period":"1month","weight":0.0099},{"period":"3month","weight":-0.0505},{"period":"6month","weight":-0.0433},{"period":"1year","weight":0.0356},{"period":"ytd","weight":-0.016}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江京新药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"31813人(较上一季度减少79.43%)","perCapita":"0股","listingDate":"2004-07-15","address":"浙江省绍兴市新昌县羽林街道新昌大道东路800号","registeredCapital":"86102万元","survey":" 浙江京新药业股份有限公司的主营业务是化学制剂、传统中药、生物制剂、化学原料药、医疗器械的研发、生产及销售。公司的主要产品是化学制剂、中成药、生物制剂、化学原料药、医疗器械。公司是第一批“中国医药企业制剂国际化先导企业”,连续多年荣登“中国化学制药行业制剂出口型优秀企业品牌”、“中国医药工业百强”和“中国化学制药企业百强榜”。","listedPrice":10.05},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"京新药业(002020)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供京新药业(002020)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"京新药业,002020,京新药业股票,京新药业股票老虎,京新药业股票老虎国际,京新药业行情,京新药业股票行情,京新药业股价,京新药业股市,京新药业股票价格,京新药业股票交易,京新药业股票购买,京新药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"京新药业(002020)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供京新药业(002020)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}